Actinium appoints Swaminathan as Chief Business Officer, Desai as CMO; Berger resigns

Actinium Pharmaceuticals, Inc.

Mark Berger resigns as CMO effective Sept 24, 2021; no disagreement with company.
Arun Swaminathan, Ph.D., appointed Chief Business and Commercial Officer; previously at Alteogen, BMS.
Avinash Desai, M.D., promoted to CMO from EVP Clinical Development; will lead BLA filing for Iomab-B.
Paul Diamond, Ph.D., appointed VP Patent and Legal Counsel; 20+ years IP experience.
Phase 3 SIERRA trial enrollment complete; commercial planning for Iomab-B begins.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Mark S. Berger

Chief Medical Officer

ATNM · Actinium Pharmaceuticals, Inc.

Effective: 2021-09-24
Filed: September 23, 2021, 7:59 PM ET

Dr. Mark S. Berger, the Chief Medical Officer of Actinium Pharmaceuticals, Inc. (the “Company”), notified the Company that he will be resigning effective as of September 24, 2021.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Mark S. Berger resigned as Chief Medical Officer at Actinium Pharmaceuticals, Inc..

Action: resigned
Role: Chief Medical Officer

Exact text from the filing

Dr. Mark S. Berger, the Chief Medical Officer of Actinium Pharmaceuticals, Inc. (the “Company”), notified the Company that he will be resigning effective as of September 24, 2021.

View on SEC.gov

Actinium Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-21-049470

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.